There are currently 2006 clinical trials in Chicago, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Northwestern University, Rush University Medical Center, University of Chicago and University of Chicago Comprehensive Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Left vs Left Randomized Clinical Trial
NCT05650658
Recruiting
The investigators aim to prospectively test the comparative effectiveness of His or Left bundle branch pacing in relation to patient centered outcomes (quality of life, physical activity, heart failure hospitalization, mortality) and comparative safety in relation to device-related complications and re-interventions (e.g., lead dislodgement, infection) relative to standard of care biventricular pacing in patients with heart failure due to left ventricular systolic dysfunction (LVEF≤50%) and with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: Rush University, Chicago, Illinois +1 locations
Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, AV Block, LBBB, RBBB, Intraventricular Conduction Delay, Pacing-Induced Cardiomyopathy
Register for Updates
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects with Myasthenia Gravis
NCT06106672
Recruiting
Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/12/2025
Locations: Insight Hospital and Medical Center, Chicago, Illinois
Conditions: Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
Register for Updates
Feasibility Trial of Sodium-GLucose CoTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease
NCT06430684
Recruiting
The goal of this study is to learn if a clinical trial of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is possible in youth with chronic kidney disease (CKD). The investigators also plan to explore whether treatment with SGLT2i (Empagliflozin) helps improve risk factors for worsening kidney and heart disease. The main questions are: 1. Is enrolling 40 youth with CKD into a clinical trial of empagliflozin feasible (ie achievable)? 2. Does taking empagliflozin for 3 months result in positi... Read More
Gender:
ALL
Ages:
Between 12 years and 25 years
Trial Updated:
02/12/2025
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Chronic Kidney Diseases, Pediatric Kidney Disease
Register for Updates
A Phase 2 Study of MZE829 in Adults with APOL1 Kidney Disease
NCT06830629
Recruiting
This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/12/2025
Locations: Research by Design, LLC, Chicago, Illinois
Conditions: Proteinuric Kidney Disease
Register for Updates
Main Study: A Study to Evaluate the Effectiveness and Safety of GAL1906 for Correction of Wrinkles in the décolletage Area Sub-study: A Follow-up Study to Evaluate the Analysis of Mammograms Following Treatment for Correction of Wrinkles in Décolletage Area in the Investigational Study 43USRV1906
NCT04717934
Recruiting
Main study: Randomized, evaluator-blinded, no treatment controlled multicenter study to evaluate safety and effectiveness of GAL1906 for the correction of wrinkles in the décolletage area. Sub-study: To evaluate imaging interpretation of mammograms in subjects who were enrolled and treated in the 43USRV1906 main study. The sub-study will determine if hyaluronic acid injections in the décolletage interfere with diagnosis or interpretation of mammogram results.
Gender:
FEMALE
Ages:
22 years and above
Trial Updated:
02/11/2025
Locations: Galderma Research Site, Chicago, Illinois
Conditions: Wrinkle
Register for Updates
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
NCT04870944
Recruiting
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells.
Gender:
ALL
Ages:
Between 12 months and 30 years
Trial Updated:
02/11/2025
Locations: Lurie Children's Hospital-Chicago, Chicago, Illinois
Conditions: Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Malignant Neoplasm in the Central Nervous System, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Recurrent Primary Malignant Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma, Refractory Primary Malignant Central Nervous System Neoplasm
Register for Updates
Once Weekly Infant Corticosteroid Trial for DMD
NCT05412394
Recruiting
The hypothesis tested here is that a lower dose of intermittent oral corticosteroids (5mg/kg/week) will be equally effective to the 10mg/kg/week dose.
Gender:
MALE
Ages:
Between 1 month and 30 months
Trial Updated:
02/11/2025
Locations: Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Duchenne Muscular Dystrophy
Register for Updates
Topical Probiotic Sinus Irrigations for Treating Chronic Sinusitis
NCT05427695
Recruiting
The purpose of this randomized study will be to determine whether topical probiotic sinus irrigations are more effective compared to saline sinus irrigation controls in the treatment of active CRS in patients who have had prior sinus surgery based on subjective and objective outcome measures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: University of Illinois Hospitals & Health Sciences System, Chicago, Illinois
Conditions: Chronic Rhinosinusitis (Diagnosis)
Register for Updates
Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer
NCT05838729
Recruiting
This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with hypofractionated radiation and a PD-1 Inhibitor in patients with unresectable, recurrent or metastatic head-neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Head Neck Cancer, Intratumoral Injection
Register for Updates
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
NCT06247787
Recruiting
This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) that has not responded to previous treatment (refractory) or that has come back after a period of improvement (recurrent). Imetelstat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs... Read More
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
02/11/2025
Locations: Lurie Children's Hospital-Chicago, Chicago, Illinois
Conditions: Recurrent Juvenile Myelomonocytic Leukemia, Refractory Juvenile Myelomonocytic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Refractory Childhood Acute Myeloid Leukemia, Refractory Childhood Myelodysplastic Syndrome
Register for Updates
Families Filming Infants Learning Movement
NCT06278961
Recruiting
The study objective is to improve accuracy in the early detection of neurodevelopmental impairment, especially CP, by evaluating the timepoint (in weeks post term age) that the Prechtl GMA is most useful for prediction of neurodevelopmental impairment at two years of age in children with and without medical complexity. The study team plans to recruit 100 healthy, term-born infants and 250 infants at risk of developing CP for a total of 350 enrolled infants.
Gender:
ALL
Ages:
Between 10 weeks and 20 weeks
Trial Updated:
02/11/2025
Locations: Feinberg School of Physical Therapy and Human Movement Sciences, Chicago, Illinois
Conditions: Infant Development, Cerebral Palsy, Motor Disorders, Neurological Disorder
Register for Updates
Metabolic Endpoints for Obstructive Sleep Apnea Following Twelfth Cranial Nerve Stimulation
NCT06317701
Recruiting
The purpose of this study is to determine if the treatment of Obstructive sleep apnea (OSA) by hypoglossal nerve stimulation (HGNS) will alter glucose metabolism. The study team will also determine if the treatment of Obstructive sleep apnea (OSA) by (hypoglossal nerve stimulation) HGNS will alter predictors of cardiovascular outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: The University of Chicago, Chicago, Illinois
Conditions: Obstructive Sleep Apnea
Register for Updates